~ MACRILEN is the First and Only FDA-Approved Oral Drug Indicated For the Diagnosis of Adult Growth Hormone Deficiency, a Rare Endocrine Disorder ~ ~ MACRILEN is Strongbridge’s Second Commercial ...
Mr. Zheng Guo Shang, General Manager of Wuzhou commented, “Wuzhou is dedicated to introducing high-quality, innovative healthcare solutions to the Greater China and Southeast Asian markets. We ...
Guildford, UK – 25 June 2015: Ergomed plc, (LSE: ERGO or 'Ergomed') a profitable UK-based company, dedicated to the provision of specialised services to the pharmaceutical industry and the development ...
Aeterna Zentaris Inc., a specialty biopharmaceutical company, announced that the company is planning to conduct a new, confirmatory phase 3 clinical study to demonstrate the efficacy of Macrilen ...
Aeterna Zentaris has announced that a comprehensive review of data obtained from the confirmatory phase 3 clinical trial of Macrilen (macimorelin) for the evaluation of growth hormone deficiency in ...
TRENTON, N.J. (Legal Newsline) – A man who purchased stock from a New Jersey biopharmaceutical company filed a class action lawsuit on Jan. 6 over allegations that the company violated the Security ...
TRENTON, N.J. (Legal Newsline) – A shareholder’s lawsuit recently filed in federal court in New Jersey is seeking class action status against a drug company over allegedly misleading statements about ...
TORONTO, ONTARIO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“COSCIENS” or the “Company”), a life sciences company focused on pharmaceutical therapies, ...
* STRONGBRIDGE - IN CONJUNCTION WITH MACRILEN DEAL, CO, CRG AMENDED EXISTING SENIOR CREDIT FACILITY TO INCREASE TOTAL POTENTIAL BORROWING TO $100 MILLION * STRONGBRIDGE BIOPHARMA-CO SHARING OVERSIGHT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results